CNCE

Concert Pharmaceuticals, Inc. [CNCE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CNCE Stock Summary

In the News

CNCE Financial details

Company Rating
-
Market Cap
401.95M
Income
-66.45M
Revenue
56.58K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
64
Optionable
No
Shortable
Yes
Earnings
02 Aug 2023
P/E
-4.67
Forward P/E
-
PEG
1.29
P/S
13860.32
P/B
3.12
P/C
-
P/FCF
-4.82
Quick Ratio
8.69
Current Ratio
9.03
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.53
EPS next Y
-
EPS next Q
-
EPS this Y
-0%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-25.7%
Revenue Q/Q
-61.9%
EPS Q/Q
9.62%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-52%
ROE
-79%
ROC
-0.59%
Gross Margin
100%
Oper. Margin
-314886%
Profit Margin
-307045%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.72-8.55
52W High
+4.62%
52W Low
+318.5%
RSI
-
Rel Volume
-
Avg Volume
2.54M
Volume
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.520519
-
-
Volatility
0%, 0%
Prev Close
0%
Price
8.37
Change
-0.12%

Something similar

Top by Market Cap
NVDA
VTSAX
CMC.DE
V
LLY
Same Sector
KILITCH.NS
SRNE
GETI-B.ST
PRM.L
SMSLIFE.NS
Check Those
CLCRX
2340.HK
CACB.TO
AGGRW
OSAGY
Similar Market Cap
SHBI
1141.HK
BSL.DE
HEIJM.AS
RTN.L

Company Profile

Healthcare Biotechnology
  • Volume Average 2.54M
  • Market Capitalization 401.95M
  • Employee 64
  • CEO Dr. Roger D. Tung Ph.D.
  • Headquarters Lexington,MA,US
  • IPO Date 2014-02-13
  • Website https://www.concertpharma.com

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.